Cargando…

Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions

Purpose: Apatinib has shown effectiveness in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib and doxorubicin combination therapy in metastatic soft tissue sarcomas (STS) and to compare the therapeutic effects of two treatments (apatinib after doxorubicin vs apatinib...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Zhichao, Wang, Xin, Liu, Zhiyong, Wang, Jiaqiang, Yao, Weitao, Zhao, Yao, Gao, Songtao, Zhang, Peng, Ge, Hong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559225/
https://www.ncbi.nlm.nih.gov/pubmed/31239779
http://dx.doi.org/10.2147/CMAR.S207150
_version_ 1783425794498887680
author Tian, Zhichao
Wang, Xin
Liu, Zhiyong
Wang, Jiaqiang
Yao, Weitao
Zhao, Yao
Gao, Songtao
Zhang, Peng
Ge, Hong
author_facet Tian, Zhichao
Wang, Xin
Liu, Zhiyong
Wang, Jiaqiang
Yao, Weitao
Zhao, Yao
Gao, Songtao
Zhang, Peng
Ge, Hong
author_sort Tian, Zhichao
collection PubMed
description Purpose: Apatinib has shown effectiveness in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib and doxorubicin combination therapy in metastatic soft tissue sarcomas (STS) and to compare the therapeutic effects of two treatments (apatinib after doxorubicin vs apatinib plus doxorubicin) on STS. Patients and methods: A total of 76 patients with metastatic STS who received apatinib and doxorubicin between May 2016 and June 2017 were retrospectively reviewed. Patients were divided into either the apatinib after doxorubicin group (in which apatinib was used after six cycles of doxorubicin chemotherapy) or the apatinib plus doxorubicin group (in which apatinib was used in combination with doxorubicin chemotherapy). Results: There were 55 patients in the apatinib after doxorubicin group and 21 patients in the apatinib plus doxorubicin group. There were significant differences between the apatinib plus doxorubicin group and the apatinib after doxorubicin group in the objective response rate (57.14% vs 25.45%, respectively, p=0.016) and average change from baseline in the target lesion size (−41.71±43.75% vs −1.89±51.61%, respectively, p=0.03). There were no significant differences in disease control rate (85.71% vs 63.64%, p=0.093) and median progression-free survival (8.8 months vs 10.3 months, p=1). Grade 3–4 adverse events were more common with apatinib plus doxorubicin than with apatinib after doxorubicin, and these included leukopenia (5.45% vs 38.1%, respectively, p=0.001), anemia (7.27% vs 28.57%, respectively, p=0.023), oral mucositis (3.64% vs 19.05%, respectively, p=0.046), transaminase increases (0% vs 14.29%, respectively, p=0.011). Conclusion: Our results do not support the use of apatinib plus doxorubicin for metastatic STS unless the specific objective is tumor shrinkage.
format Online
Article
Text
id pubmed-6559225
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher Dove
record_format MEDLINE/PubMed
spelling pubmed-65592252019-06-25 Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions Tian, Zhichao Wang, Xin Liu, Zhiyong Wang, Jiaqiang Yao, Weitao Zhao, Yao Gao, Songtao Zhang, Peng Ge, Hong Cancer Manag Res Original Research Purpose: Apatinib has shown effectiveness in treating sarcoma. This study aimed to assess the safety and efficacy of apatinib and doxorubicin combination therapy in metastatic soft tissue sarcomas (STS) and to compare the therapeutic effects of two treatments (apatinib after doxorubicin vs apatinib plus doxorubicin) on STS. Patients and methods: A total of 76 patients with metastatic STS who received apatinib and doxorubicin between May 2016 and June 2017 were retrospectively reviewed. Patients were divided into either the apatinib after doxorubicin group (in which apatinib was used after six cycles of doxorubicin chemotherapy) or the apatinib plus doxorubicin group (in which apatinib was used in combination with doxorubicin chemotherapy). Results: There were 55 patients in the apatinib after doxorubicin group and 21 patients in the apatinib plus doxorubicin group. There were significant differences between the apatinib plus doxorubicin group and the apatinib after doxorubicin group in the objective response rate (57.14% vs 25.45%, respectively, p=0.016) and average change from baseline in the target lesion size (−41.71±43.75% vs −1.89±51.61%, respectively, p=0.03). There were no significant differences in disease control rate (85.71% vs 63.64%, p=0.093) and median progression-free survival (8.8 months vs 10.3 months, p=1). Grade 3–4 adverse events were more common with apatinib plus doxorubicin than with apatinib after doxorubicin, and these included leukopenia (5.45% vs 38.1%, respectively, p=0.001), anemia (7.27% vs 28.57%, respectively, p=0.023), oral mucositis (3.64% vs 19.05%, respectively, p=0.046), transaminase increases (0% vs 14.29%, respectively, p=0.011). Conclusion: Our results do not support the use of apatinib plus doxorubicin for metastatic STS unless the specific objective is tumor shrinkage. Dove 2019-06-06 /pmc/articles/PMC6559225/ /pubmed/31239779 http://dx.doi.org/10.2147/CMAR.S207150 Text en © 2019 Tian et al. http://creativecommons.org/licenses/by-nc/3.0/ This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).
spellingShingle Original Research
Tian, Zhichao
Wang, Xin
Liu, Zhiyong
Wang, Jiaqiang
Yao, Weitao
Zhao, Yao
Gao, Songtao
Zhang, Peng
Ge, Hong
Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title_full Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title_fullStr Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title_full_unstemmed Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title_short Safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
title_sort safety and efficacy of combination therapy with apatinib and doxorubicin in metastatic soft tissue sarcomas: an observational study from multiple institutions
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6559225/
https://www.ncbi.nlm.nih.gov/pubmed/31239779
http://dx.doi.org/10.2147/CMAR.S207150
work_keys_str_mv AT tianzhichao safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT wangxin safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT liuzhiyong safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT wangjiaqiang safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT yaoweitao safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT zhaoyao safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT gaosongtao safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT zhangpeng safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions
AT gehong safetyandefficacyofcombinationtherapywithapatinibanddoxorubicininmetastaticsofttissuesarcomasanobservationalstudyfrommultipleinstitutions